In bladder cancer, miR-210-3p has been evidenced to inhibit tumor growth by targeting fibroblast growth factor receptor-like 1 (FGFRL1) and promote prostate cancer cell epithelial–mesenchymal transition (EMT) and bone metastasis by targeting the NF-kB signaling pathway [86]. This evidence concerns the gene FGFRL1 and prostate carcinoma.